Combination therapy with antibiotics and Anthrax Immune Globulin Intravenous (AIGIV) is potentially more effective than antibiotics alone in rabbit model of inhalational anthrax

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Kammanadiminti, Srinivas ^a   Patnaikuni, Ravi Kumar ^a   Comer, Jason ^b   Meister, Gabriel ^b   Sinclair, Chris ^a   Kodihalli, Shantha ^a  

^a Cangene Corporation   (Canada)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; HUMAN IMMUNOGLOBULIN; LEVOFLOXACIN; PROTECTIVE ANTIGEN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL ANTIGEN; IMMUNOGLOBULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ANTHRAX; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; INCIDENCE; LETHARGY; MALE; NEW ZEALAND WHITE (RABBIT); NONHUMAN; RESPIRATORY DISTRESS; SURVIVAL RATE; TIME TO TREATMENT; TOXEMIA; ANIMAL; BACILLUS ANTHRACIS; BLOOD; DISEASE MODEL; DRUG COMBINATION; IMMUNOLOGY; MORTALITY; RABBIT; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

ORYCTOLAGUS CUNICULUS;

ANIMALS; ANTHRAX; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTEREMIA; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; IMMUNOGLOBULINS, INTRAVENOUS; LEVOFLOXACIN; MALE; RABBITS; RESPIRATORY TRACT INFECTIONS; TOXEMIA; TREATMENT OUTCOME;

EID: 84907192018     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106393     Document Type: Article

References (25)

1. Whitby M, Ruff TA, Street AC, Fenner FJ (2002) Biological agents as weapons 2: Anthrax and plague. Med J Aust 176: 605-608.
2. Inglesby TV, Toole T 'O, Henderson DA, Bartlet AG, Ascher MS, et al. (2002) Anthrax As a Biological Weapon, 2002: updated recommendations for management. J Am Med Assoc 287: 2236-2252.
3. Shepard CW, Soriano-Gabarro M, Zell ER, Hayslett J, Lukacs S et al. (2002) Antimicrobial post exposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis 8: 1124-1132.
4. Jernigan JA, Stephens DA, Ashford DA, Omenaca C, Topiel MS et al. (2001) Bioterrorism-Related Inhalational Anthrax: The First 10 Cases Reported in the United States. Emerg Infect Dis 7: 933-944.
5. Barakat LA, Quentzel HL, Jernigan JA, Kirschke DL, Griffith K et al. (2002) Fatal Inhalational Anthrax in a 94-Year-Old Connecticut Woman. J Amer Med Assoc 287: 863-868.
6. CFR Part 601 (Subpart H): Approval of biological products when human efficacy studies are not ethical or feasible.
7. ILAR News (1989); 31(4): 5-20.
8. th Edition (2011) National Academies Press: Washington, DC. Chapter 3 - Environment, Housing, and Management. A66p.
9. Zaucha GM, Pitt LM, Estep J, Ivins BE, Friedlander AM (1998) The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch Pathol Lab Med 122: 982-92.
10. Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, et al. (2009) Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 361: 135-44.
11. Comer JE, Ray BD, Henning LN, Stark GV, Barnewall RE, et al. (2012) Characterization of a therapeutic model of inhalational anthrax using an increase in body temperature in New Zealand white rabbits as a trigger for treatment. Clin Vaccine Immunol 19(9): 1517-1525.
12. Friedlander AM, Welkos SL, Pitt ML, Ezzell JW, Worsham PL, et al. (1993) Postexposure prophylaxis against experimental inhalational anthrax. J Infect Dis 167: 1239-1242.
13. Gochenour WS Jr, Gleiser CA, Tigertt WD (1962) Observations on penicillin prophylaxis of experimental inhalation anthrax in the monkey. J Hyg 60: 29-33.
14. Henderson DW, Peacock S, Belton FC (1956) Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg 54: 28-36.
15. Jones MN, Beedham RJ, Turnbull PC, Manchee RJ (1996) Antibiotic prophylaxis for inhalational anthrax. Salisbury Med Bull (Special Supplement) 87: 127.
16. Kao ML, Bush K, Barnewall R, Estep J, Thalacker FW, et al. (2006) Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (post exposure) rhesus monkey model. Antimicrob Agents Chemother 50: 3535-3542.
17. Vietri NJ, Purcell BK, Tobery SA, Rasmussen SL, Leffel EK, et al. (2009) A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics. J Infect Dis 199: 336-41.
18. Weiss S, Kobiler D, Levy H, Pass A, Ophir Y, et al. (2011) Antibiotics cure anthrax in animal models. Antimicrob Agents Chemother 55: 1533-42.
19. Shoop WL, Y. Xiong Y, Wiltsie J, Woods A, Guo J, et al. (2005) Anthrax lethal factor inhibition. Proc Natl Acad Sci U S A 102: 7958-7963.
20. Raxibacumab Treatment of Inhalation Anthrax BLA 124359- Anti-Infectives Advisory Committee Meeting Briefing Document. Nov 2, 2012; Available: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM326185.pdf. Accessed 2014 August 19.
21. Corey A, Migone TS, Bolmer S, Fiscella M, Ward C, et al. (2013) Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/raxibacumab-treated New Zealand white rabbits. Toxins (Basel) 5(1): 120-38.
22. Altboum Z, Gozes Y, Barnea A, Pass A, White M, et al. (2002) Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs. Infect Immun 70: 6231-41.
23. Vietri NJ, Purcell BK, Lawler JV, Leffel EK, Rico P, et al. (2006) Short-course post exposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci U S A 103: 7813-6.
24. Karginov V, Robinson TM, Riemenschneider J, Golding B, Kennedy M, et al. (2004) Treatment of anthrax infection with combination of ciprofloxacin and antibodies to protective antigen of Bacillus anthracis. FEMS Immunol and Med Microbiol 40: 71-74.
25. Peterson JW, Comer JE, Noffsinger DM, Wenglikowski A, Walberg KG, et al. (2006) Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect Immun 74: 1016-1024.